All the news Showing 10 of 18 articles from: Treatment in liver transplantedGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Short-course treatment prevents hepatitis C after organ transplant Keith Alcorn / 24 June 2022 A seven-day course of direct-acting antiviral treatment started hours before an organ transplant prevented hepatitis C infection in everyone who received a transplant from a donor with hepatitis C, researchers from the Mayo ... Pre- and post-transplant antiviral treatment prevents hepatitis C transmission in all organ recipients, Canadian study finds Keith Alcorn / 14 November 2019 Adding a cholesterol-lowering drug to direct-acting antivirals (DAAs) prevented hepatitis C infection in all recipients of organ transplants from donors with hepatitis C, Jordan Feld, Research Director of the Toronto Centre for ... Advent of DAAs accompanied by dramatic improvement in survival after HCV-related liver transplant Michael Carter / 18 July 2018 Survival among people with hepatitis C virus (HCV) undergoing liver transplant has improved significantly since the introduction of direct-acting antivirals (DAAs), investigators from Catalonia report in the Journal of Hepatology. Thanks to DAAs, there ... HCV treatment allows one in four people to come off the transplant waiting list Keith Alcorn / 24 April 2017 Around one in four people with hepatitis C and decompensated cirrhosis came off the transplant waiting list in Europe after direct-acting antiviral treatment, and very few had any subsequent liver-related ... Is DAA treatment for hepatitis C reducing the need for liver transplants? Liz Highleyman / 25 January 2017 People successfully treated for hepatitis are less likely to need liver transplants and less likely to die while on a transplant waiting list, according to studies presented at the 2016 ... EASL issues new hepatitis C treatment recommendations for all genotypes Liz Highleyman / 26 September 2016 The European Association for the Study of the Liver (EASL) released its latest recommendations on treatment of hepatitis C at a special meeting last Thursday in Paris. The updated guidelines now include highly ... Improvements in HIV treatment and care have had no impact on rates of endstage liver disease among HIV-positive people with viral hepatitis Michael Carter / 01 September 2016 Incidence of endstage liver disease (ESLD) among HIV-positive people with viral hepatitis changed little between 1996 and 2010, despite major improvements in HIV treatment and care, investigators from Canada and the United States ... Daclatasvir approved for use in HIV/HCV co-infection, decompensated cirrhosis and post-transplant in the EU Keith Alcorn / 03 February 2016 The hepatitis C direct-acting antiviral daclatasvir (Daklinza) has received European Union marketing approval for use in three new populations of people with genotype 1, 3 or 4 hepatitis C infection. The NS5A inhibitor ... Liver transplants in HIV/HCV co-infection: study underlines importance of hepatitis C treatment Keith Alcorn / 29 June 2015 People with HIV and hepatitis C co-infection were significantly more likely to experience organ rejection than people with hepatitis C alone or HIV alone after undergoing a liver transplant, according to a ... Civacir immune globulin may help prevent HCV reinfection after liver transplant Liz Highleyman / 18 May 2015 Civacir, a hepatitis C immune globulin or antibody product, reduced the likelihood of hepatitis C virus infecting the new liver graft after transplantation in people who were receiving, but had not yet ... ← First12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive